Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Tempest Therapeutics, Inc. (TPST)

1.0400 +0.0200 (+1.96%)
At close: August 21 at 4:00:00 PM EDT
1.0800 +0.0400 (+3.85%)
After hours: August 21 at 7:54:46 PM EDT
Chart Range Bar
Loading chart for TPST
  • Previous Close 1.0200
  • Open 1.0100
  • Bid 0.7776 x 200
  • Ask 1.2800 x 200
  • Day's Range 1.0000 - 1.0800
  • 52 Week Range 0.8400 - 12.2300
  • Volume 123,053
  • Avg. Volume 212,908
  • Market Cap (intraday) 16.619M
  • Beta (5Y Monthly) -1.68
  • PE Ratio (TTM) --
  • EPS (TTM) -3.6800
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.00

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

www.tempesttx.com

4

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/21/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TPST
63.76%
S&P 500 (^GSPC)
12.11%

1-Year Return

TPST
88.88%
S&P 500 (^GSPC)
20.47%

3-Year Return

TPST
87.40%
S&P 500 (^GSPC)
74.43%

5-Year Return

TPST
99.41%
S&P 500 (^GSPC)
72.78%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -27.7M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-25M
-20M
-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

11.00
11.00 Average
1.0400 Current
11.00 High

Latest Rating

Date 1/22/2026
Analyst HC Wainwright & Co.
Rating Action Upgrade
Rating Buy
Price Action Announces
Price Target 11

Statistics

View More

Valuation Measures

Annual
As of 8/20/2026
  • Market Cap

    16.30M

  • Enterprise Value

    23.08M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    22.94

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -79.37%

  • Return on Equity (ttm)

    -931.14%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -40.47M

  • Diluted EPS (ttm)

    -3.6800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    779k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -15.51M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.0400 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: